

Peter J Wild

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2882234/publications.pdf>

Version: 2024-02-01

170
papers

11,128
citations

34105

52
h-index

34986

98
g-index

185
all docs

185
docs citations

185
times ranked

19763
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel RGAG1-BCOR gene fusion revealed in a somatic soft tissue sarcoma with a long follow-up. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 1107-1114.	2.8	4
2	Tumor-associated immune cell infiltrate density in penile squamous cell carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 1159-1169.	2.8	5
3	Deep learning based on hematoxylinéeosin staining outperforms immunohistochemistry in predicting molecular subtypes of gastric adenocarcinoma. <i>Journal of Pathology</i> , 2022, 257, 218-226.	4.5	13
4	Neoadjuvant Chemoradiotherapy for Oral Cavity Cancer: Predictive Factors for Response and Interim Analysis of the Prospective INVERT-Trial. <i>Frontiers in Oncology</i> , 2022, 12, 817692.	2.8	4
5	Impact of Liver Fibrosis on Survival of Patients with Intrahepatic Cholangiocarcinoma Receiving Gemcitabine-Based Chemotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 2057.	2.4	1
6	Single-cell proteomics defines the cellular heterogeneity of localized prostate cancer. <i>Cell Reports Medicine</i> , 2022, 3, 100604.	6.5	7
7	Use of MS-GUIDE for identification of protein biomarkers for risk stratification of patients with prostate cancer. <i>Clinical Proteomics</i> , 2022, 19, 9.	2.1	3
8	Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients. <i>Journal of Molecular Diagnostics</i> , 2022, , .	2.8	0
9	Implementation of Intraoperative Frozen Section During Radical Prostatectomy: Short-term Results from a German Tertiary-care Center. <i>European Urology Focus</i> , 2021, 7, 95-101.	3.1	37
10	Alterations in <i>BAP1</i> Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2021, 27, 2277-2291.	7.0	21
11	Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition. <i>Cancers</i> , 2021, 13, 1852.	3.7	3
12	Correlation of MRI-Lesion Targeted Biopsy vs. Systematic Biopsy Gleason Score with Final Pathological Gleason Score after Radical Prostatectomy. <i>Diagnostics</i> , 2021, 11, 882.	2.6	13
13	Impact of rescanning and repositioning on radiomic features employing a multi-object phantom in magnetic resonance imaging. <i>Scientific Reports</i> , 2021, 11, 14248.	3.3	21
14	A novel 5x multiplex immunohistochemical staining reveals PSMA as a helpful marker in prostate cancer with low p504s expression.. <i>Pathology Research and Practice</i> , 2021, 228, 153667.	2.3	5
15	Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	11
16	Comparison of machine learning algorithms to predict clinically significant prostate cancer of the peripheral zone with multiparametric MRI using clinical assessment categories and radiomic features. <i>European Radiology</i> , 2020, 30, 6757-6769.	4.5	33
17	Strategies to enable large-scale proteomics for reproducible research. <i>Nature Communications</i> , 2020, 11, 3793.	12.8	75
18	AKT-dependent NOTCH3 activation drives tumor progression in a model of mesenchymal colorectal cancer. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	48

#	ARTICLE	IF	CITATIONS
19	Inferring clonal composition from multiple tumor biopsies. <i>Npj Systems Biology and Applications</i> , 2020, 6, 27.	3.0	5
20	Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1299.	2.8	20
21	Convergent network effects along the axis of gene expression during prostate cancer progression. <i>Genome Biology</i> , 2020, 21, 302.	8.8	17
22	Impact of "Time-From-Biopsy-to-Prostatectomy" on Adverse Oncological Results in Patients With Intermediate and High-Risk Prostate Cancer. <i>Frontiers in Surgery</i> , 2020, 7, 561853.	1.4	5
23	Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice. <i>Blood Advances</i> , 2020, 4, 2477-2488.	5.2	15
24	Characterization of Tumor Blood Vasculature Expression of Human Invasive Bladder Cancer by Laser Capture Microdissection and Transcriptional Profiling. <i>American Journal of Pathology</i> , 2020, 190, 1960-1970.	3.8	8
25	A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 603.e1-603.e7.	1.6	13
26	CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. <i>Journal of Clinical Investigation</i> , 2020, 130, 2435-2450.	8.2	27
27	A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1836-1850.	3.8	42
28	High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. <i>Molecular Oncology</i> , 2019, 13, 2305-2328.	4.6	100
29	Comparative analysis of mRNA and protein degradation in prostate tissues indicates high stability of proteins. <i>Nature Communications</i> , 2019, 10, 2524.	12.8	35
30	BioScore (B7-H1, survivin, and Ki-67) does not predict cancer-specific mortality in surgically treated patients with renal cell carcinoma: An external validation study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 510-518.	1.6	2
31	Downregulation of SPTAN1 is related to MLH1 deficiency and metastasis in colorectal cancer. <i>PLoS ONE</i> , 2019, 14, e0213411.	2.5	22
32	Diagnostic Accuracy of a MR Protocol Acquired with and without Endorectal Coil for Detection of Prostate Cancer: A Multicenter Study. <i>Current Urology</i> , 2019, 12, 88-96.	0.6	15
33	Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants. <i>JAMA Surgery</i> , 2019, 154, e190484.	4.3	26
34	Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines. <i>IScience</i> , 2019, 21, 664-680.	4.1	52
35	Lineage-specific control of TFIID by MITF determines transcriptional homeostasis and DNA repair. <i>Oncogene</i> , 2019, 38, 3616-3635.	5.9	17
36	Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. <i>International Journal of Cancer</i> , 2019, 144, 1676-1684.	5.1	57

#	ARTICLE	IF	CITATIONS
37	Prognostic value of unifocal and multifocal positive surgical margins in a large series of robot-assisted radical prostatectomy for prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 1837-1844.	2.2	16
38	Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis. <i>Scientific Reports</i> , 2018, 8, 3477.	3.3	13
39	Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma—a single center retrospective study. <i>Pathology Research and Practice</i> , 2018, 214, 572-578.	2.3	13
40	Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 865-874.	2.5	5
41	Prevalence and causes of abnormal PSA recovery. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 341-349.	2.3	3
42	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. <i>Journal of Clinical Investigation</i> , 2018, 129, 223-229.	8.2	130
43	Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1851-1863.	1.1	6
44	Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers. <i>Life Science Alliance</i> , 2018, 1, e201800042.	2.8	51
45	Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing. <i>Pathology Research and Practice</i> , 2018, 214, 957-963.	2.3	11
46	Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression. <i>Frontiers in Oncology</i> , 2018, 8, 40.	2.8	15
47	Automated Gleason grading of prostate cancer tissue microarrays via deep learning. <i>Scientific Reports</i> , 2018, 8, 12054.	3.3	278
48	Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 10284-10293.	1.8	44
49	Mouse genetic background influences whether <i>HrasG12V</i> expression plus <i>Cdkn2a</i> knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma. <i>Oncotarget</i> , 2018, 9, 19753-19766.	1.8	6
50	Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer. <i>Prostate</i> , 2017, 77, 549-556.	2.3	34
51	Detecting circulating tumor DNA in renal cancer: An open challenge. <i>Experimental and Molecular Pathology</i> , 2017, 102, 255-261.	2.1	28
52	Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing — a case report. <i>BMC Cancer</i> , 2017, 17, 66.	2.6	13
53	Combined mutation in <i>Vhl</i> , <i>Trp53</i> and <i>Rb1</i> causes clear cell renal cell carcinoma in mice. <i>Nature Medicine</i> , 2017, 23, 869-877.	30.7	101
54	A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients. <i>Scientific Data</i> , 2017, 4, 170014.	5.3	21

#	ARTICLE	IF	CITATIONS
55	Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. <i>Nature Medicine</i> , 2017, 23, 1046-1054.	30.7	145
56	Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. <i>Nature Medicine</i> , 2017, 23, 1063-1071.	30.7	240
57	Evidence of renal angiomyolipoma neoplastic stem cells arising from renal epithelial cells. <i>Nature Communications</i> , 2017, 8, 1466.	12.8	20
58	Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung. <i>Cancer Cytopathology</i> , 2017, 125, 30-40.	2.4	47
59	RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy. <i>Oncotarget</i> , 2017, 8, 5774-5788.	1.8	22
60	Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2017.	4.1	20
61	Oncogenic HrasG12V expression plus knockdown of Cdkn2a using ecotropic lentiviral vectors induces high-grade endometrial stromal sarcoma. <i>PLoS ONE</i> , 2017, 12, e0186102.	2.5	3
62	Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years. <i>Journal of Cancer</i> , 2017, 8, 323-331.	2.5	18
63	Detection of <i>CCNE1/URI</i> (19q12) amplification by <i>in situ</i> hybridisation is common in high grade and type II endometrial cancer. <i>Oncotarget</i> , 2017, 8, 14794-14805.	1.8	16
64	Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death. <i>Oncotarget</i> , 2017, 8, 31765-31774.	1.8	15
65	Computational Pathology. , 2017, , 263-279.		0
66	Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (<sc>ERSPC</sc>) and Prostate Cancer Prevention Trial (<sc>PCPT</sc>) risk calculators: independent validation and comparison in a contemporary European cohort. <i>BJU International</i> , 2016, 117, 401-408.	2.5	76
67	Combined deletion of <i>Vhl</i> , <i>Trp53</i> and <i>Kif3a</i> causes cystic and neoplastic renal lesions. <i>Journal of Pathology</i> , 2016, 239, 365-373.	4.5	23
68	Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity. <i>Scientific Reports</i> , 2016, 6, 24146.	3.3	28
69	Clinical impact of prostate biopsy undergrading in an academic and community setting. <i>World Journal of Urology</i> , 2016, 34, 1481-1490.	2.2	6
70	TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. <i>Cancer Cell</i> , 2016, 29, 846-858.	16.8	228
71	Influence of Varying Assessment Parameters on the Diagnostic Accuracy of Magnetic Resonance Imaging in the Local Staging of Prostate Cancer. <i>Urologia Internationalis</i> , 2016, 96, 309-314.	1.3	4
72	Formation of Renal Cysts and Tumors in <i>Vhl/Trp53</i> -Deficient Mice Requires HIF1 \pm and HIF2 \pm . <i>Cancer Research</i> , 2016, 76, 2025-2036.	0.9	40

#	ARTICLE	IF	CITATIONS
73	Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels. <i>Molecular Oncology</i> , 2016, 10, 825-837.	4.6	20
74	Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer. <i>Journal of Pathology Informatics</i> , 2016, 7, 3.	1.7	10
75	Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer. <i>Oncology Letters</i> , 2015, 10, 2753-2760.	1.8	13
76	Dosimetry and First Clinical Evaluation of the New ¹⁸ F-Radiolabeled Bombesin Analogue BAY 864367 in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 372-378.	5.0	70
77	Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 402.	6.3	229
78	In cystectomy specimens with bladder cancer whole organ embedding increases the detection rate of histopathological parameters, but not of those with prognostic significance. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 423-432.	2.8	7
79	Combined Deletion of Vhl and Kif3a Accelerates Renal Cyst Formation. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2778-2788.	6.1	20
80	Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer. <i>Journal of Clinical Pathology</i> , 2015, 68, 819-824.	2.0	34
81	Biological Relevance and Therapeutic Potential of the Hypusine Modification System. <i>Journal of Biological Chemistry</i> , 2015, 290, 18343-18360.	3.4	48
82	Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer—what has gone wrong? A blueprint for the way forward in biomarker studies. <i>British Journal of Cancer</i> , 2015, 112, 140-148.	6.4	43
83	A novel germline mutation of PDGFR- β might be associated with clinical response of colorectal cancer to regorafenib. <i>Annals of Oncology</i> , 2015, 26, 246-248.	1.2	8
84	A versatile modular vector system for rapid combinatorial mammalian genetics. <i>Journal of Clinical Investigation</i> , 2015, 125, 1603-1619.	8.2	62
85	Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells. <i>Oncotarget</i> , 2015, 6, 32748-32760.	1.8	81
86	Myoglobin expression in prostate cancer is correlated to androgen receptor expression and markers of tumor hypoxia. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 419-427.	2.8	22
87	Regulation and function of the atypical cadherin FAT1 in hepatocellular carcinoma. <i>Carcinogenesis</i> , 2014, 35, 1407-1415.	2.8	46
88	Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. <i>BMC Clinical Pathology</i> , 2014, 14, 10.	1.8	61
89	hKPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation. <i>Journal of Pathology</i> , 2014, 234, 239-252.	4.5	23
90	Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. <i>Nature Methods</i> , 2014, 11, 417-422.	19.0	1,430

#	ARTICLE	IF	CITATIONS
91	Hypermethylation of the <i>GABRE</i> miR-452 miR-224 Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2014, 20, 2169-2181.	7.0	86
92	SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts. <i>Neoplasia</i> , 2014, 16, 14-W10.	5.3	145
93	Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. <i>Science</i> , 2014, 346, 85-89.	12.6	200
94	Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic Leukemia (SM-CMML) by Next Generation Sequencing. <i>Experimental Hematology and Oncology</i> , 2014, 3, 18.	5.0	5
95	Retroperitoneal teratoma with somatic malignant transformation: A papillary renal cell carcinoma in a testicular germ cell tumour metastasis following platinum-based chemotherapy. <i>BMC Urology</i> , 2013, 13, 9.	1.4	18
96	Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 437-443.	2.8	26
97	TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. <i>Experimental and Molecular Pathology</i> , 2013, 95, 235-241.	2.1	74
98	Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 623-631.	2.8	26
99	Heterogeneous expression and functional relevance of the ubiquitin carboxyl-terminal hydrolase L1 in melanoma. <i>International Journal of Cancer</i> , 2013, 133, n/a-n/a.	5.1	19
100	Combined mutation of <i>Vhl</i> and <i>Trp53</i> causes renal cysts and tumours in mice. <i>EMBO Molecular Medicine</i> , 2013, 5, 949-964.	6.9	131
101	Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08). <i>European Urology</i> , 2013, 64, 150-158.	1.9	120
102	KRAS, BRAF, and TP53 Deep Sequencing for Colorectal Carcinoma Patient Diagnostics. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 299-311.	2.8	27
103	Endocan Is Upregulated on Tumor Vessels in Invasive Bladder Cancer Where It Mediates VEGF-Induced Angiogenesis. <i>Cancer Research</i> , 2013, 73, 1097-1106.	0.9	150
104	DNA Methylation Signatures for Prediction of Biochemical Recurrence After Radical Prostatectomy of Clinically Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3250-3258.	1.6	117
105	Differential Patterns of Large Tumor Antigen-Specific Immune Responsiveness in Patients with BK Polyomavirus-Positive Prostate Cancer or Benign Prostatic Hyperplasia. <i>Journal of Virology</i> , 2012, 86, 8461-8471.	3.4	15
106	Intrafascial Dissection Significantly Increases Positive Surgical Margin and Biochemical Recurrence Rates after Robotic-Assisted Radical Prostatectomy. <i>Urologia Internationalis</i> , 2012, 89, 17-24.	1.3	16
107	Promoter methylation of aminopeptidase N/CD13 in malignant melanoma. <i>Carcinogenesis</i> , 2012, 33, 781-790.	2.8	13
108	Fatal outcome after heart transplantation caused by <i>Aspergillus lentulus</i> . <i>Transplant Infectious Disease</i> , 2012, 14, E60-3.	1.7	44

#	ARTICLE	IF	CITATIONS
109	Expression of Serotonin Receptors in Human Hepatocellular Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 5902-5910.	7.0	66
110	FOXA1 Promotes Tumor Progression in Prostate Cancer and Represents a Novel Hallmark of Castration-Resistant Prostate Cancer. <i>American Journal of Pathology</i> , 2012, 180, 848-861.	3.8	115
111	A Seven-Marker Signature and Clinical Outcome in Malignant Melanoma: A Large-Scale Tissue-Microarray Study with Two Independent Patient Cohorts. <i>PLoS ONE</i> , 2012, 7, e38222.	2.5	67
112	Profiling gastrin-releasing peptide receptor in prostate tissues: Clinical implications and molecular correlates. <i>Prostate</i> , 2012, 72, 318-325.	2.3	111
113	Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. <i>Nature Genetics</i> , 2012, 44, 685-689.	21.4	1,300
114	p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans. <i>EMBO Molecular Medicine</i> , 2012, 4, 808-824.	6.9	60
115	Downregulation of zinc finger protein 132 in prostate cancer is associated with aberrant promoter hypermethylation and poor prognosis. <i>International Journal of Cancer</i> , 2012, 130, 885-895.	5.1	23
116	Down-Regulation of Methylthioadenosine Phosphorylase (MTAP) Induces Progression of Hepatocellular Carcinoma via Accumulation of 5-Deoxy-5-Methylthioadenosine (MTA). <i>American Journal of Pathology</i> , 2011, 178, 1145-1152.	3.8	54
117	The Androgen-Regulated Calcium-Activated Nucleotidase 1 (CANT1) Is Commonly Overexpressed in Prostate Cancer and Is Tumor-Biologically Relevant in Vitro. <i>American Journal of Pathology</i> , 2011, 178, 1847-1860.	3.8	31
118	Identification of new genes associated with melanoma. <i>Experimental Dermatology</i> , 2011, 20, 502-507.	2.9	37
119	Novel Prognostic Markers in the Serum of Patients With Castration-Resistant Prostate Cancer Derived From Quantitative Analysis of the Pten Conditional Knockout Mouse Proteome. <i>European Urology</i> , 2011, 60, 1235-1243.	1.9	49
120	Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 643-651.	2.5	6
121	Increased expression of transcription factor TFAP2 \pm correlates with chemosensitivity in advanced bladder cancer. <i>BMC Cancer</i> , 2011, 11, 135.	2.6	35
122	Serine threonine kinase 15 amplification in normal urothelium of cystectomy specimens is no prognostic factor in urothelial carcinoma of the bladder. <i>Pathology Research and Practice</i> , 2011, 207, 161-163.	2.3	0
123	KPNA2 Expression Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2011, 17, 1111-1121.	7.0	93
124	Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3342-3347.	7.1	175
125	MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer. <i>PLoS ONE</i> , 2011, 6, e21366.	2.5	47
126	Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma. <i>Experimental Dermatology</i> , 2010, 19, e251-7.	2.9	35

#	ARTICLE	IF	CITATIONS
127	Infinite mixture-of-experts model for sparse survival regression with application to breast cancer. BMC Bioinformatics, 2010, 11, S8.	2.6	5
128	Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer, 2010, 10, 273.	2.6	74
129	The Application of Artificial Intelligence to Microarray Data: Identification of a Novel Gene Signature to Identify Bladder Cancer Progression. European Urology, 2010, 57, 398-406.	1.9	52
130	Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology, 2010, 51, 1244-1254.	7.3	182
131	Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma. PPAR Research, 2010, 2010, 1-11.	2.4	41
132	Mining Tissue Microarray Data to Uncover Combinations of Biomarker Expression Patterns that Improve Intermediate Staging and Grading of Clear Cell Renal Cell Cancer. Clinical Cancer Research, 2010, 16, 88-98.	7.0	94
133	Expression of the Lipid Transporters ABCA3 and ABCA1 is Diminished in Human Breast Cancer Tissue. Hormone and Metabolic Research, 2010, 42, 102-109.	1.5	60
134	AID protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with poor prognosis and complex genetic alterations. Modern Pathology, 2010, 23, 177-186.	5.5	33
135	Low Frequency of Epigenetic Events in Urothelial Tumors in Young Patients. Journal of Urology, 2010, 184, 459-463.	0.4	28
136	Reduced Expression of Fibroblast Growth Factor Receptor 2IIIb in Hepatocellular Carcinoma Induces a More Aggressive Growth. American Journal of Pathology, 2010, 176, 1433-1442.	3.8	52
137	MDR1 and ERCC1 Expression Predict Outcome of Patients with Locally Advanced Bladder Cancer Receiving Adjuvant Chemotherapy. Neoplasia, 2010, 12, 628-636.	5.3	131
138	Exploring the Nuclear Envelope of Herpes Simplex Virus 1-Infected Cells by High-Resolution Microscopy. Journal of Virology, 2009, 83, 408-419.	3.4	41
139	Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. Journal of Experimental Medicine, 2009, 206, 221-232.	8.5	193
140	Neogenesis and maturation of transient Golgi-like cisternae in a simple eukaryote. Journal of Cell Science, 2009, 122, 2846-2856.	2.0	62
141	The Bayesian group-Lasso for analyzing contingency tables. , 2009, , .		45
142	Detection of Urothelial Bladder Cancer Cells in Voided Urine Can Be Improved by a Combination of Cytology and Standardized Microsatellite Analysis. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1798-1806.	2.5	38
143	Loss of VHL and Hypoxia Provokes PAX2 Up-Regulation in Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2009, 15, 3297-3304.	7.0	44
144	Genetic and Epigenetic <i>SLC18A2</i> Silencing in Prostate Cancer Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy. Clinical Cancer Research, 2009, 15, 1400-1410.	7.0	26

#	ARTICLE	IF	CITATIONS
145	Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. <i>BMC Cancer</i> , 2009, 9, 217.	2.6	81
146	Nuclear detection of Y-boxprotein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. <i>BMC Cancer</i> , 2009, 9, 410.	2.6	55
147	Expression of the Endothelin Axis in Noninvasive and Superficially Invasive Bladder Cancer: Relation to Clinicopathologic and Molecular Prognostic Parameters. <i>European Urology</i> , 2009, 56, 837-847.	1.9	23
148	Reassessing the Current UICC/AJCC TNM Staging for Renal Cell Carcinoma. <i>European Urology</i> , 2009, 56, 636-643.	1.9	114
149	Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. <i>Hepatology</i> , 2009, 49, 1602-1609.	7.3	110
150	Frequent expression of the novel cancer testis antigen MAGEa€C2/CTa€C10 in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2009, 124, 352-357.	5.1	63
151	No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer. <i>International Journal of Cancer</i> , 2009, 125, 2205-2208.	5.1	20
152	Randomized Tree Ensembles for Object Detection in Computational Pathology. <i>Lecture Notes in Computer Science</i> , 2009, , 367-378.	1.3	5
153	Nuclear karyopherin β 2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity. <i>International Journal of Cancer</i> , 2008, 123, 1433-1438.	5.1	70
154	Nutritional depletion and its relationship to respiratory impairment in patients with chronic respiratory failure due to COPD or restrictive thoracic diseases. <i>European Journal of Clinical Nutrition</i> , 2008, 62, 436-443.	2.9	42
155	Renal cell carcinoma marker reliably discriminates central nervous system haemangioblastoma from brain metastases of renal cell carcinoma. <i>Histopathology</i> , 2008, 52, 674-681.	2.9	25
156	Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. <i>BMC Cancer</i> , 2008, 8, 42.	2.6	139
157	ADAM9 Expression is a Significant and Independent Prognostic Marker of PSA Relapse in Prostate Cancer. <i>European Urology</i> , 2008, 54, 1097-1108.	1.9	69
158	Prediction of Progression of Nona€Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study. <i>European Urology</i> , 2008, 54, 835-844.	1.9	148
159	Microarray comparative genomic hybridization analysis of tubular breast carcinoma shows recurrent loss of the CDH13 locus on 16q. <i>Human Pathology</i> , 2008, 39, 1621-1629.	2.0	31
160	HER3 Is a Determinant for Poor Prognosis in Melanoma. <i>Clinical Cancer Research</i> , 2008, 14, 5188-5197.	7.0	142
161	The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma. <i>Gut</i> , 2008, 57, 243-251.	12.1	61
162	Weakly Supervised Cell Nuclei Detection and Segmentation on Tissue Microarrays of Renal Clear Cell Carcinoma. <i>Lecture Notes in Computer Science</i> , 2008, , 173-182.	1.3	9

#	ARTICLE	IF	CITATIONS
163	A potential predictive marker for response to interferon in malignant melanoma. JDDG - Journal of the German Society of Dermatology, 2007, 5, 456-459.	0.8	15
164	FGFR3 Mutations and a Normal CK20 Staining Pattern Define Low-Grade Noninvasive Urothelial Bladder Tumours. European Urology, 2007, 52, 760-768.	1.9	84
165	Tissue Microarray Analysis of Methylthioadenosine Phosphorylase Protein Expression in Melanocytic Skin Tumors. Archives of Dermatology, 2006, 142, 471-6.	1.4	16
166	Molecular Profiling of Laser-Microdissected Matched Tumor and Normal Breast Tissue Identifies Karyopherin $\beta 2$ as a Potential Novel Prognostic Marker in Breast Cancer. Clinical Cancer Research, 2006, 12, 3950-3960.	7.0	145
167	Laser Microdissection for Microsatellite Analysis in Colon and Breast Cancer. , 2005, 293, 93-102.		2
168	Gene Expression Profiling of Progressive Papillary Noninvasive Carcinomas of the Urinary Bladder. Clinical Cancer Research, 2005, 11, 4415-4429.	7.0	97
169	RNA expression profiling of normal and tumor cells following photodynamic therapy with 5-aminolevulinic acid ⁶⁶ induced protoporphyrin IX in vitro. Molecular Cancer Therapeutics, 2005, 4, 516-528.	4.1	42
170	High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. International Journal of Oncology, 2005, 27, 385-91.	3.3	13